dc.contributor.author | Ruark, E | |
dc.contributor.author | Seal, S | |
dc.contributor.author | McDonald, H | |
dc.contributor.author | Zhang, F | |
dc.contributor.author | Elliot, A | |
dc.contributor.author | Lau, K | |
dc.contributor.author | Perdeaux, E | |
dc.contributor.author | Rapley, E | |
dc.contributor.author | Eeles, R | |
dc.contributor.author | Peto, J | |
dc.contributor.author | Kote-Jarai, Z | |
dc.contributor.author | Muir, K | |
dc.contributor.author | Nsengimana, J | |
dc.contributor.author | Shipley, J | |
dc.contributor.author | UK Testicular Cancer Collaboration (UKTCC), | |
dc.contributor.author | Bishop, DT | |
dc.contributor.author | Stratton, MR | |
dc.contributor.author | Easton, DF | |
dc.contributor.author | Huddart, RA | |
dc.contributor.author | Rahman, N | |
dc.contributor.author | Turnbull, C | |
dc.date.accessioned | 2018-08-22T13:43:58Z | |
dc.date.issued | 2013-06-01 | |
dc.identifier.citation | Nature genetics, 2013, 45 (6), pp. 686 - 689 | |
dc.identifier.issn | 1061-4036 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2371 | |
dc.identifier.eissn | 1546-1718 | |
dc.identifier.doi | 10.1038/ng.2635 | |
dc.description.abstract | Testicular germ cell tumor (TGCT) is the most common cancer in young men and is notable for its high familial risks. So far, six loci associated with TGCT have been reported. From genome-wide association study (GWAS) analysis of 307,291 SNPs in 986 TGCT cases and 4,946 controls, we selected for follow-up 694 SNPs, which we genotyped in a further 1,064 TGCT cases and 10,082 controls from the UK. We identified SNPs at nine new loci (1q22, 1q24.1, 3p24.3, 4q24, 5q31.1, 8q13.3, 16q12.1, 17q22 and 21q22.3) showing association with TGCT (P < 5 × 10(-8)), which together account for an additional 4-6% of the familial risk of TGCT. The loci include genes plausibly related to TGCT development. PRDM14, at 8q13.3, is essential for early germ cell specification, and DAZL, at 3p24.3, is required for the regulation of germ cell development. Furthermore, PITX1, at 5q31.1, regulates TERT expression and is the third TGCT-associated locus implicated in telomerase regulation. | |
dc.format | Print-Electronic | |
dc.format.extent | 686 - 689 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | UK Testicular Cancer Collaboration (UKTCC) | |
dc.subject | Humans | |
dc.subject | Neoplasms, Germ Cell and Embryonal | |
dc.subject | Testicular Neoplasms | |
dc.subject | Genetic Predisposition to Disease | |
dc.subject | RNA-Binding Proteins | |
dc.subject | DNA-Binding Proteins | |
dc.subject | Transcription Factors | |
dc.subject | Repressor Proteins | |
dc.subject | Risk Factors | |
dc.subject | Gene Frequency | |
dc.subject | Linkage Disequilibrium | |
dc.subject | Polymorphism, Single Nucleotide | |
dc.subject | Male | |
dc.subject | Genome-Wide Association Study | |
dc.title | Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2013-04-10 | |
rioxxterms.versionofrecord | 10.1038/ng.2635 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2013-06 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Nature genetics | |
pubs.issue | 6 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Predisposition & Translation Genetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Predisposition & Translation Genetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.publication-status | Published | |
pubs.volume | 45 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Predisposition & Translation Genetics | |
icr.researchteam | Genetic Susceptibility | |
icr.researchteam | Sarcoma Molecular Pathology | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
icr.researchteam | Oncogenetics | |
dc.contributor.icrauthor | Eeles, Rosalind | |
dc.contributor.icrauthor | Kote-Jarai, Zsofia | |
dc.contributor.icrauthor | Shipley, Janet | |
dc.contributor.icrauthor | Huddart, Robert | |
dc.contributor.icrauthor | Turnbull, Clare | |